Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > NASH market and competition

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Apr 05, 2021 7:16pm

120 Views

Post# 32939207

RE:RE:RE:RE:RE:RE:RE:RE:RE:NASH market and competition

We can accept the low valuation or we can try to find a reason, I go with the latter.

Exposure is the first hurdle next one is conviction, the valuation of the company is a projection of market’s perception. TH initially was a biotech specialized in commercializing drugs, the valuation was based on net revenues since then they have gone through a transition so now they are also an R&D company in two niche fields, there is no approved drug for NASH so the market has to understand what are the probability of approval and post approval financial opportunities to value the programs, there aren’t any precedents to use as a reference so there is work to be done.

For instance how likely their science can get the drugs approved and post approval the size of the market, the pricing of the drug, the potential market share, competition, patient compliance, cost of goods, the profit margin, marketing cost, sale force costs/size, administration costs other variable and fixed costs etc., so this is what the company needs to do not only to come to that magic number before committing to any project but a proforma financial statement also can be used to attract institutional investors, mutual funds, analysts and sophisticated retail investors, same applies to the PDC program again no precedents.

So short answer to the question is absolutely yes the investors need to be educated so do the analysts. One could presume all the prep work should have been done very early in the process so at some point it should be communicated to the market, the sooner the better imo.

jeffm34 wrote:
So are you saying that every single investor is wrong except for a handful of people posting on this board?

scarlet1967 wrote: Believe me I haven't missed that and it's real so is the reason why.

jeffm34 wrote:
You are missing the only thing that matters. The current share price the market has ascribed to TH's NASH program. It's not an oversight by investors. It's a reality.

scarlet1967 wrote: am I missing something here?